Refractory pericarditis treated with concurrent subcutaneous immunoglobulin and interleukin 1 inhibitor therapy

Patients with refractory pericarditis have been treated with intravenous immunoglobulin or interleukin 1 (IL1) receptor antagonist (Anakinra) with limited success. Separate or combined therapy with subcutaneous immunoglobulin (HyQvia) and IL1 inhibitor (Rilonacept) for refractory pericarditis has not been previously described.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Gans, S. Gagne, D. Hsu, A. Rubinstein Tags: M233 Source Type: research